explore -WSS

explore

author：knowledge 2025-09-30 22:28:03 - browse：8111

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

entertainment

WSS

EQRx, failed developer of low

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

PEPFAR is under serious threat — and so is global health

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Sage hopes for a blockbuster in antidepressant now before FDA

hotspot

explore

focus

Alkermes shareholders re

What the US credit downgrade means for the economy, your finances

New air purifier tech could be key to improving indoor air quality

WATCH: Why do bright lights make us see spots?

Heart attack and stroke risk calculators need revising

The high personal cost of affirmative action for Black doctors

State Dept. review finds Biden bears some blame for Afghanistan failures

What the airline industry can learn from medicine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Pence says 'crackpot lawyers' told Trump what he wanted to hear

focus

FDA panel endorses Alnylam’s heart drug — after picking it apart

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

WATCH: Why do bright lights make us see spots?

Sage hopes for a blockbuster in antidepressant now before FDA

Adults seen as increasingly susceptible to measles

EQRx, failed developer of low

focus

focus

entertainment

entertainment